On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.

ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene.

Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study.

Key initial results from the OLE study show that continuous treatment with acoramidis led to:

• A confirmed sustained improvement relative to placebo in time to the first event ( cardiovascular-related hospitalizations (CVH) or All-Cause Mortality (ACM)) starting at Month 3 in ATTRibute-CM
• A statistically significant reduction in ACM alone of 36% by Month 36 (p=0.009) and 34% by Month 42 (p=0.006).
• A significant reduction of composite ACM and CVH by 46% at Month 36 and 48% at Month 42, building upon the previously presented 42% reduction at Month 30 in ATTRibute-CM.
• Acoramidis continues to be well tolerated, with no new clinically significant safety signals identified in this long-term evaluation.

The OLE data build on previously reported results from ATTRibute-CM in which acoramidis demonstrated clinically important treatment effects on mortality, CVH, and quality of life, further supporting that greater transthyretin (TTR) stabilization can improve clinical outcomes for patients.

This included a 50% reduction in the cumulative frequency of CVH relative to placebo at Month 30.

BridgeBio’s marketing application is under FDA review, with a PDUFA action date of November 29, 2024. It also has a marketing application to the European Medicines Agency, with a decision expected in 2025.

BridgeBio has granted Bayer AG (OTC:BAYRY) exclusive rights to commercialize ceramides for ATTR-CM in Europe.

William Blair writes that reducing overall mortality is crucial for competing in the ATTR-CM market against Pfizer Inc’s (NYSE:PFE) tafamidis, which already includes proven mortality benefits on its label from the ATTR-ACT trial.

The analyst writes, “While Bridge Bio continues to publish analyses of acoramidis demonstrating the TTR stabilizer is safe and efficacious, we deem an on-label claim to all-cause mortality benefit as an important factor for market share in the lucrative, but competitive, ATTR-CM space.”

Price Action: BBIO stock is up 0.85% at $22.54 at the last check on Tuesday.

Read Next:

• United Airlines Gears Up For Holiday Travel Surge To Europe: Details

Latest Ratings for BBIO

View More Analyst Ratings for BBIO

View the Latest Analyst Ratings

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.